Knowledge graph · Cancer
Smoldering Systemic Mastocytosis
hematologic malignancy
- Identifier
- CI-CAN-00008458
- Entity page
- /cancer/smoldering-systemic-mastocytosis ↗
- Edges
- 3
- Neighbours
- 3 trials
- Drawn
- 3 of 3 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Smoldering Systemic Mastocytosis studied in …STUDIED_INderived3 of 3 | ||||||||
| → studied in | NCT04910685Phase 2/Phase 3 · recruiting (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 3 trials mapped (2 active) | — | — | Smoldering Systemic Mastocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05186753Phase 2 · active not recruiting (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 3 trials mapped (2 active) | |||||||